CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
泛癌分析揭示 SMARCAL1 表达与多种癌症的免疫细胞浸润及不良预后相关
英文原题：Pan-cancer analysis reveals SMARCAL1 expression is associated with immune cell infiltration and poor prognosis in various cancers.
查看英文原题
Pan-cancer analysis reveals SMARCAL1 expression is associated with immune cell infiltration and poor prognosis in various cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管免疫检查点抑制在癌症免疫治疗中尤其显示出前景，但它并不总是有效。近期研究表明SMARCAL1可能在肿瘤免疫逃逸中发挥作用，但其泛癌作用尚不清楚。我们利用TCGA、GTEx和CCLE数据库对SMARCAL1进行了全面分析，评估了其在33种癌症类型中的表达、遗传改变、表观遗传修饰及其临床相关性。我们的研究结果表明，SMARCAL1在几种癌症中过表达，如Glioma、LUAD、KIRC和LIHC，并影响预后。SMARCAL1升高与Glioma、LUAD和LIHC的不良结局相关，但在KIRC中与更好的生存相关。我们还发现SMARCAL1表达与13种癌症中的DNA甲基化存在显著关联。此外，SMARCAL1表达与免疫浸润相关，提示其可作为癌症免疫治疗的潜在治疗靶点。本研究强调了需要进一步研究SMARCAL1以增强免疫治疗策略。
展开英文摘要原文
Although immune checkpoint inhibition in particular has shown promise in cancer immunotherapy, it is not always efficient. Recent studies suggest that SMARCAL1 may play a role in tumor immune evasion, yet its pan-cancer role is unclear.
We conducted a comprehensive analysis of SMARCAL1 using TCGA, GTEx, and CCLE databases, evaluating its expression, genetic alterations, epigenetic modifications, and their clinical correlations across 33 cancer types.
Our findings indicate that SMARCAL1 is overexpressed in several cancers, such as Glioma, LUAD, KIRC, and LIHC, impacting prognosis. Elevated SMARCAL1 is linked to poor outcomes in Glioma, LUAD, and LIHC but correlates with better survival in KIRC.
We also found significant associations between SMARCAL1 expression and DNA methylation in 13 cancers.
Furthermore, SMARCAL1 expression correlates with immune infiltration, suggesting it as a potential therapeutic target in cancer immunotherapy.
This study underscores the need for further research on SMARCAL1 to enhance immunotherapeutic strategies.
论文信息
- 作者
- Zhao WJ、Wang ML、Zhao YF、Zhao WP、Huang QH、Lu ZW、Jia F、Shi JJ
- 第一作者单位
- Department of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361005, Fujian, China.China
- 通讯作者单位
- Department of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361005, Fujian, China. wangzx@xmu.edu.cn.China
- 期刊
- Scientific reports2025 Feb 24
- 原文标识
- PubMed 39994264 · DOI 10.1038/s41598-025-88955-9
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →